Products04

We believe that our lead program ND007, a bispecific antibody fragment, holds tremendous promise for the treatment of autoimmune diseases.

Pipeline

Hit discovery
Lead optimization
Preclincal PoC
IND-enabling studies
Phase I
ND007 (anti-IL23RxCD3) Chronic inflammation
ND009 (anti-TNF) IBD Partner: Tillotts
ND016 (multispecific) Chronic inflammation Partner: Intarcia
ND017 Metabolic disease Partner: Intarcia
Multiple programs (multispecific) Chronic inflammation
Multiple programs (multispecific) Immuno-oncology

ND007 – autoimmunity

ND009 – IBD

ND016 – autoimmunity

ND017 – metabolic disease

ND007 – autoimmunity

We believe that our lead program ND007, a bispecific antibody fragment, holds tremendous promise in the treatment of autoimmune diseases.

It has become clear that a class of lymphocytes called autoreactive pathogenic T cells (Tpaths) that express IL-23 receptor (IL23R) is among the main culprits in many autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

In autoimmune disorders, Tpaths, once activated, produce pro-inflammatory cytokines that in their turn set in motion a cascade leading to local or systemic inflammation. To date, most novel therapeutic strategies have focused on these cytokines, one at a time. A number of these strategies have commercially been quite successful, despite a significant number of non-responders. In addition, it has been unexpectedly difficult to translate the relative success of one cytokine in one disease to another disease.

Clearly, the intricate interplay between cytokines in different diseases and stages of a disease has a high variability and sets a natural limit to the impact of engaging a single cytokine. By moving upstream, ND007 aims to directly engage the very Tpath cells that are the prime source of the various cytokines (e.g. TNF, IL-17, IL-22 or GM-CSF) that induce chronic and/or relapsing inflammation. These particular Tpath cells have a recognizable signature: they express IL23R. This prompted us to design a mechanism to specifically eliminate IL23R-expressing cells. Our anti IL23RxCD3 bispecific antibody fragment ND007 is engineered to bind on one hand to IL23R and on the other to CD3, which recruits T-killer cells to lyse the IL23R-expressing Tpath cells. We expect that this approach has the potential to demonstrate superior efficacy.

What is more, there is evidence that ND007 also depletes pathogenic memory T cells, potentially leading to long-lasting disease modification or even to cure. In multiple sclerosis there are currently three approved mechanisms for immune-cell depletion, respectively eliminating CD52-, CD20- and IL2R-positive cells. Compared to ND007 these are much less specific, and therefore we expect ND007 in addition to superior efficacy to display a superior safety profile as well.

ND009 – IBD

ND009 is an anti-TNF antibody fragment that is being developed for inflammatory bowel disease (IBD), a chronic inflammation of the digestive tract that primarily includes ulcerative colitis and Crohn’s disease. Anti-TNF therapy has been shown to reduce the need for hospitalization and surgical interventions in IBD and improve quality of life. Numab’s highly stable antibody fragment ND009 has best-in-class potency, and is licensed to Tillotts Pharma AG for the development and commercialization of innovative formulations.

ND016 – autoimmunity

ND016 is a novel multispecific antibody fragment-based molecule for the treatment of severe autoimmune disorders. In close collaboration with Intarcia Numab is developing a highly potent and stable lead molecule suitable for long-term sustained release from Intarcia’s miniaturized implantable Duros device, aiming at a once- or twice-yearly therapy. Intarcia retains the rights to commercialize this asset under license from Numab.

ND017 – metabolic disease

ND017 is a novel antibody fragment-based molecule for the treatment of metabolic disorders. Numab is developing a highly potent and stable lead molecule suitable for long-term sustained release from Intarcia’s miniaturized implantable Duros device, aiming at a once- or twice-yearly therapy. Intarcia retains the rights to commercialize this asset under license from Numab.